Sign in

    Benjamin Mee

    Research Associate at Stephens Inc.

    Benjamin Mee is a Research Associate at Stephens Inc., specializing in Diagnostics, Genomics, and Proteomics equity research. He covers companies within these subsectors but specific publicly disclosed company names under his direct coverage are not listed; his quantitative performance metrics and analyst rankings are not available in public outlets. Mee began his research career as an associate analyst at UBS, then spent two years in Corporate Development and Investor Relations before rejoining Stephens, where he currently focuses on sector-specific public equity analysis. He holds a B.B.A. in Finance and a Certificate in Investment Management from the University of Wisconsin-Milwaukee and is registered with FINRA as a Broker.

    Benjamin Mee's questions to OCX leadership

    Benjamin Mee's questions to OCX leadership • Q3 2024

    Question

    Inquired about the trend of transplant centers proactively seeking the RUO product, specific use cases where the product has a competitive advantage, the key decision-makers for adoption, and common sales hurdles.

    Answer

    The company is seeing proactive interest, citing a pediatric unit that adopted the test to avoid long turnaround times with send-out labs. Key differentiators include utility in monitoring anti-CD38 drug therapy and the early detection of antibody-mediated rejection (AMR), with data showing a 10-month lead time. Adoption requires buy-in from both lab managers and clinical transplant leadership. The main sales hurdle is the need for labs to adopt a new instrument (Bio-Rad QX600) for a single test, but the product's strong value proposition is helping to overcome this.

    Ask Fintool Equity Research AI